JP2016129515A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016129515A5 JP2016129515A5 JP2016027812A JP2016027812A JP2016129515A5 JP 2016129515 A5 JP2016129515 A5 JP 2016129515A5 JP 2016027812 A JP2016027812 A JP 2016027812A JP 2016027812 A JP2016027812 A JP 2016027812A JP 2016129515 A5 JP2016129515 A5 JP 2016129515A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- cells
- tat
- tat protein
- proliferation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000015609 tat Gene Products Human genes 0.000 claims 6
- 108010038756 tat Gene Products Proteins 0.000 claims 6
- 210000000822 Killer Cells, Natural Anatomy 0.000 claims 5
- 210000004027 cells Anatomy 0.000 claims 4
- 102000037240 fusion proteins Human genes 0.000 claims 3
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 230000004083 survival Effects 0.000 claims 3
- 230000026683 transduction Effects 0.000 claims 3
- 238000010361 transduction Methods 0.000 claims 3
- 230000035755 proliferation Effects 0.000 claims 2
- 206010059512 Apoptosis Diseases 0.000 claims 1
- 102000024678 Bcl-2 family Human genes 0.000 claims 1
- 108091011726 Bcl-2 family Proteins 0.000 claims 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 1
- 101700075357 MYC Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000000875 corresponding Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000001737 promoting Effects 0.000 claims 1
Claims (4)
- インビトロで培養された1以上のNK細胞の細胞増殖又は細胞生存の1以上を促進する方法であって、
前記1以上のNK細胞に、
(a)Tatタンパク質のタンパク質形質導入ドメイン;および
(b)前記Tatタンパク質のタンパク質形質導入ドメインと付着し、細胞生存及び増殖を促進することが可能であり、かつ細胞内で生物活性を有する、MYCタンパク質、
を含む融合タンパク質を提供するステップ;ならびに
培地中で前記1以上のNK細胞を培養するステップ、
を含み、かつ
前記融合タンパク質に暴露されなかった対応する細胞と比較して、前記1以上のNK細胞の前記増殖又は生存の1以上が増加している、
前記方法。 - 前記Tatタンパク質がHIV−1 Tatタンパク質である、請求項1記載の方法。
- 前記Tatタンパク質が配列番号10記載のアミノ酸配列を含む、請求項1記載の方法。
- 前記1以上のNK細胞に、アポトーシスを抑制するBcl−2ファミリーメンバー、およびTatタンパク質のタンパク質形質導入ドメインを含む融合タンパク質を提供するステップをさらに含む、請求項1記載の方法。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72813105P | 2005-10-18 | 2005-10-18 | |
US60/728,131 | 2005-10-18 | ||
US76599306P | 2006-02-06 | 2006-02-06 | |
US60/765,993 | 2006-02-06 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014108137A Division JP6302356B2 (ja) | 2005-10-18 | 2014-05-26 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017166334A Division JP6655050B2 (ja) | 2005-10-18 | 2017-08-31 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016129515A JP2016129515A (ja) | 2016-07-21 |
JP2016129515A5 true JP2016129515A5 (ja) | 2016-09-01 |
Family
ID=37963171
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008536713A Pending JP2009511081A (ja) | 2005-10-18 | 2006-10-18 | 条件的に不死化された長期幹細胞およびそのような細胞を作製および使用する方法 |
JP2012221023A Active JP5726148B2 (ja) | 2005-10-18 | 2012-10-03 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
JP2014108137A Active JP6302356B2 (ja) | 2005-10-18 | 2014-05-26 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
JP2016027812A Pending JP2016129515A (ja) | 2005-10-18 | 2016-02-17 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
JP2017166334A Expired - Fee Related JP6655050B2 (ja) | 2005-10-18 | 2017-08-31 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
JP2019006759A Expired - Fee Related JP6797221B2 (ja) | 2005-10-18 | 2019-01-18 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
JP2020119082A Active JP7078673B2 (ja) | 2005-10-18 | 2020-07-10 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
JP2022025236A Pending JP2022065146A (ja) | 2005-10-18 | 2022-02-22 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008536713A Pending JP2009511081A (ja) | 2005-10-18 | 2006-10-18 | 条件的に不死化された長期幹細胞およびそのような細胞を作製および使用する方法 |
JP2012221023A Active JP5726148B2 (ja) | 2005-10-18 | 2012-10-03 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
JP2014108137A Active JP6302356B2 (ja) | 2005-10-18 | 2014-05-26 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017166334A Expired - Fee Related JP6655050B2 (ja) | 2005-10-18 | 2017-08-31 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
JP2019006759A Expired - Fee Related JP6797221B2 (ja) | 2005-10-18 | 2019-01-18 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
JP2020119082A Active JP7078673B2 (ja) | 2005-10-18 | 2020-07-10 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
JP2022025236A Pending JP2022065146A (ja) | 2005-10-18 | 2022-02-22 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
Country Status (13)
Country | Link |
---|---|
US (7) | US8883507B2 (ja) |
EP (1) | EP1942739B1 (ja) |
JP (8) | JP2009511081A (ja) |
KR (2) | KR101441693B1 (ja) |
CN (2) | CN105483088B (ja) |
AT (1) | ATE491022T1 (ja) |
AU (1) | AU2006304392B2 (ja) |
CA (2) | CA2626525C (ja) |
DE (1) | DE602006018768D1 (ja) |
HK (2) | HK1126623A1 (ja) |
IL (7) | IL296832A (ja) |
IN (1) | IN2014DN06624A (ja) |
WO (1) | WO2007047583A2 (ja) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8883507B2 (en) * | 2005-10-18 | 2014-11-11 | The Regents Of The University Of Colorado | Conditionally immortalized long-term hematopoietic stem cells and methods of making and using such cells |
ES2511791T3 (es) | 2006-05-31 | 2014-10-23 | Children's Medical Center Corporation | Células madre mesenquimales positivas para ABCB5 como moduladoras de inmunidad |
GB0619500D0 (en) * | 2006-10-03 | 2006-11-08 | Univ Keele | Treatment of fibrosis |
WO2008112922A2 (en) | 2007-03-13 | 2008-09-18 | National Jewish Medical And Research Center | Methods for generation of antibodies |
WO2009139930A2 (en) | 2008-05-16 | 2009-11-19 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
EP2746387A1 (en) * | 2008-07-21 | 2014-06-25 | Taiga Biotechnologies, Inc. | Differentiated anucleated cells and method for preparing the same |
DK2966084T3 (en) | 2008-08-28 | 2018-08-06 | Taiga Biotechnologies Inc | MODULATORS OF MYC, PROCEDURES FOR USING SAME AND PROCEDURES FOR IDENTIFYING SUBSTANCES MODULATING MYC |
ES2796111T3 (es) | 2008-11-14 | 2020-11-25 | Brigham & Womens Hospital Inc | Métodos terapéuticos relacionados con células madre cancerosas |
US11542328B2 (en) | 2008-11-14 | 2023-01-03 | The Brigham And Women's Hospital, Inc. | Therapeutic and diagnostic methods relating to cancer stem cells |
EP2448967B1 (en) * | 2009-06-29 | 2015-04-15 | Ilya B. Leskov | Non-human mammal model of human hematopoietic cancer |
KR101834687B1 (ko) * | 2009-09-15 | 2018-03-05 | 고쿠리츠다이가쿠호우진 도쿄다이가쿠 | 분화 세포의 신규 제조법 |
AU2014240253B2 (en) * | 2009-09-15 | 2017-08-03 | The University Of Tokyo | Novel Method for Producing Differentiated Cells |
EP2498796B1 (en) * | 2009-11-09 | 2017-12-27 | AAL Scientifics, Inc. | Treatment of heart disease |
CN103025865A (zh) * | 2010-05-06 | 2013-04-03 | 干细胞医药有限公司 | 用于个性化医疗的干细胞库 |
US10034900B2 (en) | 2010-09-30 | 2018-07-31 | National University Corporation Kumamoto University | Method of producing myeloid blood cells |
US8889630B2 (en) | 2011-12-23 | 2014-11-18 | Carlos Lopez | Method for hair regrowth using Granulocyte-Colony Stimulating Factor |
US20130171115A1 (en) * | 2011-12-30 | 2013-07-04 | Gang Li | Cell-mediated gene therapy for cancer using mesenchymal stem cells expressing a suicide gene |
CA3133302A1 (en) * | 2012-07-20 | 2014-01-23 | Taiga Biotechnologies, Inc. | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment comprising a myc polypeptide |
US9801912B2 (en) | 2013-02-19 | 2017-10-31 | Va Boston Healthcare System | ABCB5(+) stem cells for treating ocular disease |
US9365825B2 (en) * | 2013-03-11 | 2016-06-14 | Taiga Biotechnologies, Inc. | Expansion of adult stem cells in vitro |
US10272115B2 (en) * | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
DK2994173T3 (en) | 2013-05-10 | 2021-10-11 | Childrens Medical Center | Wound healing and tissue engineering |
KR101638403B1 (ko) * | 2013-07-17 | 2016-07-11 | 아주대학교산학협력단 | RGMc를 유효성분으로 포함하는 줄기세포 유도용 배지 조성물 및 이를 이용한 줄기세포의 유도방법 |
WO2015020993A2 (en) * | 2013-08-05 | 2015-02-12 | The Trustees Of The University Of Pennsylvania | RNAi COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA |
CN103509101B (zh) * | 2013-08-12 | 2016-11-02 | 中国科学院广州生物医药与健康研究院 | 一种扩增脐带血造血干细胞的细胞因子及其培养基 |
US20180051253A1 (en) | 2015-03-18 | 2018-02-22 | The Regents Of The University Of California | Methods of preventing and reversing stem cell aging |
CN106148266A (zh) * | 2015-04-20 | 2016-11-23 | 烟台赛泽生物技术有限公司 | 一种免疫细胞用培养基及该培养基的添加剂 |
CN104928247B (zh) * | 2015-07-02 | 2018-03-23 | 广州赛莱拉干细胞科技股份有限公司 | 一种神经干细胞培养基及神经干细胞贴壁培养方法 |
WO2017015320A1 (en) * | 2015-07-21 | 2017-01-26 | Children's Medical Center Corporation | Pd-l1 expressing hematopoietic stem cells and uses |
EP3347026A4 (en) * | 2015-09-09 | 2019-05-08 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | GENEMANIPULATION OF MACROPHAGES FOR IMMUNOTHERAPY |
US11534466B2 (en) | 2016-03-09 | 2022-12-27 | Aal Scientifics, Inc. | Pancreatic stem cells and uses thereof |
CN105695511A (zh) * | 2016-04-13 | 2016-06-22 | 中国人民解放军第三军医大学 | 一种永生化毛囊干细胞系及其制备方法 |
CN105713880A (zh) * | 2016-04-20 | 2016-06-29 | 广东艾时代生物科技有限责任公司 | 一种造血干细胞体外扩增培养的无血清培养基及其应用 |
CN106279403B (zh) * | 2016-08-16 | 2019-06-11 | 长春市海兰深生物医学技术有限公司 | 一种检测天然肺癌相关抗体的组合物、试剂盒和方法 |
CA3045017A1 (en) | 2016-12-02 | 2018-06-07 | Taiga Biotechnologies, Inc. | Nanoparticle formulations |
CN106754728B (zh) * | 2016-12-30 | 2020-05-15 | 中国人民解放军总医院 | 后肾间充质细胞系及其制备方法与应用 |
FR3068366B1 (fr) * | 2017-06-30 | 2023-11-24 | Francais Du Sang Ets | Procede de production de progeniteurs erythroides |
AU2018308982A1 (en) * | 2017-08-03 | 2020-02-13 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of cancer |
US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
US11879137B2 (en) | 2017-09-22 | 2024-01-23 | The Children's Medical Center Corporation | Treatment of type 1 diabetes and autoimmune diseases or disorders |
US12023357B2 (en) | 2017-10-13 | 2024-07-02 | Hackensack University Medical Center | Rejuvenated aged hematopoietic stem cells and methods of use |
CN107937342B (zh) * | 2017-11-06 | 2021-07-06 | 中国人民解放军第四军医大学 | 一种通过内皮细胞来源的外泌体扩增神经干细胞的方法 |
CN108070567A (zh) * | 2018-01-19 | 2018-05-25 | 皓昇莱生物制药有限公司 | 一种永生化的尿液来源细胞株及其构建方法 |
EP3864141A2 (en) * | 2018-10-12 | 2021-08-18 | Reneuron Limited | Induced pluripotent cell comprising a controllable transgene for conditional immortalisation |
GB201902068D0 (en) * | 2019-02-14 | 2019-04-03 | Cambridge Entpr Ltd | Methods of reactivating proliferative capacity non-proliferative tissues |
US20220282220A1 (en) * | 2019-07-24 | 2022-09-08 | Sl Bigen Inc. | Method for preparation of immortalized stem cell line and use thereof |
CN110622921B (zh) * | 2019-09-29 | 2021-06-15 | 江苏大学 | 阿尔茨海默病病变区FoxG1过表达小鼠模型的构建方法及应用 |
GB202005494D0 (en) * | 2020-04-15 | 2020-05-27 | Reneuron Ltd | Induced pluripotent cell comprising a contollable transgene for conditional immortalisation |
KR20220057859A (ko) | 2020-10-30 | 2022-05-09 | 전상수 | 펜터리 |
WO2022097716A1 (ja) | 2020-11-06 | 2022-05-12 | 株式会社Trans Chromosomics | 可逆的不死化細胞の製造方法 |
CN113444730A (zh) * | 2021-03-17 | 2021-09-28 | 昆明市延安医院 | 一种原发性肝细胞klotho基因转导干细胞筛选构建方法 |
WO2023277153A1 (ja) * | 2021-06-30 | 2023-01-05 | 国立大学法人千葉大学 | 骨髄系共通前駆細胞(cmp)又は骨髄球系前駆細胞の増殖性を向上させる方法 |
CN113583965A (zh) * | 2021-08-05 | 2021-11-02 | 大连干细胞与精准医学创新研究院 | 一种条件永生化人神经干细胞来源细胞膜纳米囊泡制剂及其制备方法和应用 |
JPWO2023190271A1 (ja) | 2022-03-28 | 2023-10-05 |
Family Cites Families (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
JPS62501537A (ja) * | 1984-12-21 | 1987-06-25 | テクニクロン・リサ−チ・パ−トナ−ズ・ワン | リンパ球細胞を電気的に不滅化するための方法 |
DE3531430A1 (de) | 1985-09-03 | 1987-03-05 | Biotest Pharma Gmbh | Verfahren zur gewinnung von komponenten aus einer fluessigkeit mit in raeumlich getrennten bereichen vorliegenden komponenten |
US4963489A (en) * | 1987-04-14 | 1990-10-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
US4900322A (en) | 1986-09-22 | 1990-02-13 | Adams James D | Blood component pooling valve and kit |
US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
US5399493A (en) | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
US5670617A (en) | 1989-12-21 | 1997-09-23 | Biogen Inc | Nucleic acid conjugates of tat-derived transport polypeptides |
US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
US5849288A (en) | 1990-01-15 | 1998-12-15 | Yeda Research And Development Co. Ltd. | Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5912170A (en) | 1991-03-07 | 1999-06-15 | The General Hospital Corporation | Redirection of cellular immunity by protein-tyrosine kinase chimeras |
US5843728A (en) | 1991-03-07 | 1998-12-01 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
US6753162B1 (en) | 1991-03-07 | 2004-06-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
US5851828A (en) | 1991-03-07 | 1998-12-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
US6004811A (en) | 1991-03-07 | 1999-12-21 | The Massachussetts General Hospital | Redirection of cellular immunity by protein tyrosine kinase chimeras |
IE920716A1 (en) | 1991-03-07 | 1992-09-09 | Gen Hospital Corp | Redirection of cellular immunity by receptor chimeras |
AU781922B2 (en) | 1991-12-17 | 2005-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5289858A (en) | 1991-12-18 | 1994-03-01 | Abbott Laboratories | System for accommodating withdrawal of liquid from a bulk supply |
US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
ATE173016T1 (de) | 1992-08-21 | 1998-11-15 | Biogen Inc | Von tat abgeleitete transportpolypeptide |
US5580760A (en) | 1993-02-22 | 1996-12-03 | The United States Of America As Represented By The Department Of Health And Human Services | FUSE binding protein and cDNA therefor |
US5824837A (en) | 1993-07-22 | 1998-10-20 | Merck & Co., Inc. | Expression of human interleukin-1β in a transgenic animal |
US5599705A (en) | 1993-11-16 | 1997-02-04 | Cameron; Robert B. | In vitro method for producing differentiated universally compatible mature human blood cells |
ES2204944T3 (es) | 1994-03-03 | 2004-05-01 | Alexion Pharmaceuticals, Inc. | Genes y proteinas de fusion inhibidores del complemento terminal. |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
US6713247B1 (en) | 1996-09-03 | 2004-03-30 | Signal Pharmaceuticials, Inc. | Human CNS cell lines and methods of use therefor |
EP0975370B9 (en) | 1997-05-21 | 2004-11-03 | The Board Of Trustees Of The Leland Stanford Junior University | Composition and method for enhancing transport across biological membranes |
EP0893493A3 (de) | 1997-07-21 | 2002-12-04 | Aventis Pharma Deutschland GmbH | Genetisch veränderte Zellen und deren Verwendung in der Prophylaxe oder Therapie von Erkrankungen |
GB9720585D0 (en) | 1997-09-26 | 1997-11-26 | Smithkline Beecham Biolog | Vaccine |
CA2314267A1 (en) | 1997-12-10 | 1999-06-17 | Washington University | Anti-pathogen system and methods of use thereof |
US6861257B1 (en) | 1998-04-08 | 2005-03-01 | Shionogi & Co., Ltd. | Methods for isolation of osteoclast precursor cells and inducing their differentiation into osteoclasts |
US6835567B1 (en) * | 1998-04-14 | 2004-12-28 | Signal Pharmaceuticals, Inc. | PNS cell lines and methods of use therefor |
US6451558B1 (en) | 1998-08-03 | 2002-09-17 | Novartis Ag | Genes in the control of hematopoiesis |
US6913925B1 (en) * | 1998-08-12 | 2005-07-05 | Signal Pharmaceuticals Llc | Human mesencephalon cell lines and methods of use therefor |
JP2003514765A (ja) | 1999-02-28 | 2003-04-22 | ワシントン ユニバーシティー | 新規形質導入分子およびその使用方法 |
AU4070500A (en) * | 1999-04-05 | 2000-10-23 | Biocrystal Limited | Assay kits and methods for immune complex-mediated activation involving shed antigens |
US6451601B1 (en) * | 1999-04-12 | 2002-09-17 | Modex Therapeutiques, S.A. | Transiently immortalized cells for use in gene therapy |
AU4342900A (en) | 1999-04-12 | 2000-11-14 | Modex Therapeutiques, S.A. | Transiently immortalized cells for use in gene therapy |
US6358739B1 (en) | 1999-04-12 | 2002-03-19 | Modex Therapeutiques, S.A. | Transiently immortalized cells |
US7135287B1 (en) | 1999-10-02 | 2006-11-14 | Biosite, Inc. | Human antibodies |
US7311920B1 (en) | 1999-10-08 | 2007-12-25 | University Of Maryland Biotechnology Institute | Virus coat protein/receptor chimeras and methods of use |
CA2390011A1 (en) | 1999-11-10 | 2001-05-17 | Rigel Pharmaceuticals, Inc. | Methods and compositions comprising renilla gfp |
EP1103615A1 (en) * | 1999-11-25 | 2001-05-30 | Universite De Geneve | Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors |
US20010049393A1 (en) | 1999-12-07 | 2001-12-06 | Whitehead Institute For Biomedical Research | Methods for defining MYC target genes and uses thereof |
EP1285577A4 (en) | 2000-05-15 | 2007-05-09 | Sonoko Habu | CHIMERIC MOUSE HAVING IMMUNITY CREATED BY USE OF HUMAN CD34 POSITIVE CELLS AND USE THEREOF |
US20020155127A1 (en) | 2000-06-02 | 2002-10-24 | Danher Wang | Genetic vaccine against human immunodeficiency virus |
US20030072794A1 (en) | 2000-06-09 | 2003-04-17 | Teni Boulikas | Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes |
US20070248618A1 (en) | 2004-03-16 | 2007-10-25 | Cohen David I | Tat-Based vaccine Compositions and Methods of Making and Using Same |
AU2001296354A1 (en) | 2000-09-25 | 2002-04-02 | Baylor College Of Medicine | Improved system for regulation of transgene expression |
JP2004521616A (ja) | 2000-10-30 | 2004-07-22 | カロバイオス, インコーポレイテッド | 競合的選択による親和性成熟 |
JP2004528012A (ja) | 2000-11-01 | 2004-09-16 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 改善された免疫応答を誘導し得る発現ベクターおよびこのベクターの使用方法 |
ES2295218T3 (es) | 2000-12-01 | 2008-04-16 | Central Institute For Experimental Animals | Procedimiento para la produccion de un raton adecuado para el prendimiento, la diferenciacion y la proliferacion de celulas heterogeneas, raton producido mediante este procedimiento y utilizacion del raton. |
WO2002057436A2 (en) | 2001-01-19 | 2002-07-25 | Gendel Limited | Red blood cell from a transgenic animal as vehicle for polypeptide delivery |
JP3454818B1 (ja) * | 2001-03-16 | 2003-10-06 | 直哉 小林 | 肝臓細胞の増殖方法、該方法により得られる肝臓細胞、およびその用途 |
JP2004537293A (ja) * | 2001-05-31 | 2004-12-16 | ノバルティス アクチエンゲゼルシャフト | 新規なエストロゲン受容体リガンド結合ドメイン変異体及び新規なリガンド及び医薬組成物 |
JP4317940B2 (ja) | 2001-08-31 | 2009-08-19 | イミュノコア・リミテッド | 物質 |
CN1408850A (zh) * | 2001-09-18 | 2003-04-09 | 王虹 | 人血树突状细胞永生化技术 |
CN100506978C (zh) | 2001-09-21 | 2009-07-01 | 中国人民解放军军事医学科学院野战输血研究所 | 一种新的造血干/祖细胞的富集方法及其体外定向诱导分化 |
GB0124391D0 (en) | 2001-10-11 | 2001-11-28 | Gene Expression Technologies L | Control of gene expression |
WO2003039462A2 (en) | 2001-11-02 | 2003-05-15 | Tanox, Inc. | B-cell lymphoma specific antigen for use in diagnosis and treatment of b-cell malignancies |
EP1321034A1 (en) * | 2001-12-21 | 2003-06-25 | Pfizer Products Inc. | Disruption of the phosphodieterase 10 gene |
US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
US7670781B2 (en) | 2002-01-03 | 2010-03-02 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an agent that provides a primary activation signal and another agent that provides a co-stimulatory signal |
CA2476556A1 (en) | 2002-02-13 | 2003-08-21 | Duke University | Modulation of immune response by non-peptide binding stress response polypeptides |
CN1240439C (zh) | 2002-03-28 | 2006-02-08 | 南京凯基生物科技发展有限公司 | 肿瘤基因开关药物 |
US7211191B2 (en) | 2004-09-30 | 2007-05-01 | Thermogenesis Corp. | Blood component separation method and apparatus |
US20030226159A1 (en) * | 2002-04-16 | 2003-12-04 | Bachoo Robert M. | Cancer models |
GB2387599B (en) | 2002-04-17 | 2005-08-10 | Jason Peter Brown | Methods for producing antibodies |
CN105566497A (zh) * | 2002-05-10 | 2016-05-11 | 新世纪药品有限公司 | 融合铁蛋白在疫苗和其他方面的应用 |
SI1506223T1 (sl) * | 2002-05-16 | 2006-04-30 | Bavarian Nordic As | Fuzijski protein HIV regulatornih/akcesorskih proteinov |
ES2439874T3 (es) * | 2002-05-29 | 2014-01-27 | Regeneron Pharmaceuticals, Inc. | Sistema de expresión en eucariotas inducible |
EP1545204B1 (en) | 2002-09-06 | 2016-08-10 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
EP1549748B1 (en) | 2002-10-09 | 2014-10-01 | Immunocore Ltd. | Single chain recombinant t cell receptors |
EP1408114B1 (de) | 2002-10-11 | 2007-01-03 | Imvision GmbH | Moduläre Antigen-Transporter Moleküle (MAT-Moleküle) zur Modulierung von Immunreaktionen, zugehörige Konstrukte, Verfahren und Verwendungen |
WO2004035535A2 (en) | 2002-10-15 | 2004-04-29 | Yeda Research And Development Co. Ltd. | Erythrocyte differentiation factor, gene encoding same, and methods of use thereof |
PT1558643E (pt) | 2002-11-09 | 2009-08-24 | Immunocore Ltd | Apresentação de um receptor das células t |
CA2508052A1 (en) | 2002-12-05 | 2004-06-17 | Imperial College Innovations Limited | Control of apoptosis using a complex of an oligonucleotide and a regulatory peptide |
GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
WO2004084805A2 (en) | 2003-03-19 | 2004-10-07 | The J. David Gladstone Institutes | Acetylated tat polypeptides and methods of use thereof |
AU2003300359A1 (en) | 2003-05-08 | 2004-12-13 | Xcyte Therapies, Inc. | Generation and isolation of antigen-specific t cells |
WO2005014785A2 (en) | 2003-06-18 | 2005-02-17 | The George Washington University | Conditionally-immortalized hematopoietic progenitor cell lines |
CA2529752A1 (en) | 2003-06-20 | 2005-09-15 | The Regents Of The University Of California | Polypeptide transduction and fusogenic peptides |
IL161903A0 (en) | 2003-07-17 | 2005-11-20 | Gamida Cell Ltd | Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs |
US7705049B2 (en) | 2004-01-21 | 2010-04-27 | New York University | Methods for treating non-melanoma cancers with PABA |
JP2005232148A (ja) * | 2004-02-03 | 2005-09-02 | Technion Research & Development Foundation Ltd | 神経保護剤としてプロパルギルアミンの使用 |
CA2566363C (en) | 2004-05-19 | 2014-12-16 | Avidex Ltd | High affinity ny-eso t cell receptor |
DE602005009825D1 (de) | 2004-05-19 | 2008-10-30 | Medigene Ltd | Verfahren zur verbesserung von t-zellrezeptoren |
DK1791865T3 (da) | 2004-06-29 | 2010-11-01 | Immunocore Ltd | Celler der udtrykker en modificeret T-cellerecptor |
US20060068469A1 (en) | 2004-08-17 | 2006-03-30 | Research Development Foundation | Bacterial vector systems |
GB0420963D0 (en) * | 2004-09-21 | 2004-10-20 | Reneuron Ltd | Hepatocyte |
US7767453B2 (en) * | 2004-10-20 | 2010-08-03 | Whitehead Institute For Biomedical Research | Cultured hematopoietic stem cells and method for expansion and analysis thereof |
WO2007067183A1 (en) | 2005-12-09 | 2007-06-14 | The Regents Of The University Of California | Derivation of unlimited quantities of neutrophils or monocyte/dendritic cells |
US20060156422A1 (en) | 2005-01-10 | 2006-07-13 | Medical Research Council | Methods and compositions for the generation of antibodies |
US20070098715A1 (en) | 2005-03-25 | 2007-05-03 | Seth Ettenberg | Antibodies against the tenascin major antigens |
CA2609342A1 (en) | 2005-04-26 | 2006-11-02 | Andrei L. Gartel | Nucleoside compounds and methods of use thereof |
WO2006125962A2 (en) | 2005-05-25 | 2006-11-30 | Medigene Limited | T cell receptors which specifically bind to vygfvracl-hla-a24 |
DE602006012513D1 (de) | 2005-08-26 | 2010-04-08 | Healthpartners Res Foundation | Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin |
US20070047583A1 (en) | 2005-08-29 | 2007-03-01 | Siemens Aktiengesellschaft | Method for using a short address in a packet header |
US8883507B2 (en) | 2005-10-18 | 2014-11-11 | The Regents Of The University Of Colorado | Conditionally immortalized long-term hematopoietic stem cells and methods of making and using such cells |
EP1942948A4 (en) | 2005-11-04 | 2010-03-03 | Alnylam Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE NAV1.8 GENE |
EP1792627A1 (en) | 2005-12-05 | 2007-06-06 | ImVisioN AG | Modulation of the immune response by administration of intralymphatic transduction allergen (ITAG-)-molecules |
US8088379B2 (en) | 2006-09-26 | 2012-01-03 | The United States Of America As Represented By The Department Of Health And Human Services | Modified T cell receptors and related materials and methods |
EP2087000A2 (en) | 2006-09-29 | 2009-08-12 | Immunocore Ltd. | T cell therapies |
WO2008112922A2 (en) | 2007-03-13 | 2008-09-18 | National Jewish Medical And Research Center | Methods for generation of antibodies |
EP2214670A2 (en) | 2007-11-02 | 2010-08-11 | Taiga Biotechnologies, Inc. | Compounds for treating abnormal cellular proliferation |
EP2955222B1 (en) | 2008-03-17 | 2018-09-12 | The Scripps Research Institute | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
WO2009139930A2 (en) | 2008-05-16 | 2009-11-19 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
WO2009149956A2 (en) | 2008-06-13 | 2009-12-17 | Life & Brain Gmbh | Fusion protein and use thereof |
EP2746387A1 (en) | 2008-07-21 | 2014-06-25 | Taiga Biotechnologies, Inc. | Differentiated anucleated cells and method for preparing the same |
DK2966084T3 (en) | 2008-08-28 | 2018-08-06 | Taiga Biotechnologies Inc | MODULATORS OF MYC, PROCEDURES FOR USING SAME AND PROCEDURES FOR IDENTIFYING SUBSTANCES MODULATING MYC |
AU2009313290B2 (en) | 2008-11-06 | 2016-04-21 | Indiana University Research & Technology Corporation | Materials and methods to enhance hematopoietic stem cells engraftment procedures |
CA2743669C (en) | 2008-11-24 | 2018-10-16 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | High affinity t cell receptor and use thereof |
WO2011100477A2 (en) | 2010-02-10 | 2011-08-18 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
US20120107317A1 (en) | 2010-10-27 | 2012-05-03 | The University Of Hong Kong | Use of cytoplasmic c-myc for regulating immune responses |
WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
US20140378389A1 (en) | 2011-09-15 | 2014-12-25 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage |
CN107557334B (zh) | 2012-05-03 | 2021-06-25 | 弗雷德哈钦森癌症研究中心 | 增强亲和力的t细胞受体及其制备方法 |
DE102012209673A1 (de) | 2012-06-08 | 2013-12-24 | Artcline Gmbh | Verfahren zum Herstellen einer Leukozytenpräparation und Leukozytenpräparation |
CA3133302A1 (en) | 2012-07-20 | 2014-01-23 | Taiga Biotechnologies, Inc. | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment comprising a myc polypeptide |
KR102250696B1 (ko) | 2012-07-27 | 2021-05-12 | 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 | T 세포 수용체 조작 |
US20140109246A1 (en) | 2012-09-24 | 2014-04-17 | The Regents Of The University Of Colorado, A Body Corporate | Methods of generating xenochimaeric mice with tumor and hematopoietic system from the same heterologous species |
GB2508414A (en) | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
EP3821898A1 (en) | 2013-03-01 | 2021-05-19 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods of producing enriched populations of tumor-reactive t cells from tumor |
ES2771251T3 (es) | 2013-03-01 | 2020-07-06 | Us Health | Métodos de producción de poblaciones enriquecidas de células T reactivas con tumores a partir de sangre periférica |
US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
US9365825B2 (en) | 2013-03-11 | 2016-06-14 | Taiga Biotechnologies, Inc. | Expansion of adult stem cells in vitro |
KR20200138445A (ko) | 2014-04-24 | 2020-12-09 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용 |
AU2015371265B2 (en) | 2014-12-24 | 2021-06-03 | Neximmune, Inc | Nanoparticle compositions and methods for immunotherapy |
CN109952313B (zh) | 2016-01-15 | 2023-12-19 | 伯克利之光生命科技公司 | 生产患者特异性抗癌治疗剂的方法和其治疗方法 |
US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
-
2006
- 2006-10-18 US US11/583,970 patent/US8883507B2/en active Active
- 2006-10-18 DE DE602006018768T patent/DE602006018768D1/de active Active
- 2006-10-18 AU AU2006304392A patent/AU2006304392B2/en not_active Ceased
- 2006-10-18 AT AT06826025T patent/ATE491022T1/de active
- 2006-10-18 WO PCT/US2006/040379 patent/WO2007047583A2/en active Application Filing
- 2006-10-18 CA CA2626525A patent/CA2626525C/en active Active
- 2006-10-18 IL IL296832A patent/IL296832A/en unknown
- 2006-10-18 CN CN201510760532.XA patent/CN105483088B/zh not_active Expired - Fee Related
- 2006-10-18 KR KR1020087011791A patent/KR101441693B1/ko active IP Right Grant
- 2006-10-18 KR KR1020137028338A patent/KR101441843B1/ko active IP Right Grant
- 2006-10-18 CN CN200680045545.8A patent/CN101330830B/zh not_active Expired - Fee Related
- 2006-10-18 IN IN6624DEN2014 patent/IN2014DN06624A/en unknown
- 2006-10-18 CA CA3065947A patent/CA3065947C/en active Active
- 2006-10-18 IL IL286053A patent/IL286053B2/en unknown
- 2006-10-18 JP JP2008536713A patent/JP2009511081A/ja active Pending
- 2006-10-18 EP EP06826025A patent/EP1942739B1/en active Active
-
2008
- 2008-04-17 IL IL190946A patent/IL190946A/en active IP Right Grant
-
2009
- 2009-06-22 HK HK09105588.8A patent/HK1126623A1/zh not_active IP Right Cessation
- 2009-06-22 HK HK16110996.5A patent/HK1222890A1/zh unknown
-
2010
- 2010-02-05 US US12/701,383 patent/US9150831B2/en active Active
-
2012
- 2012-10-03 JP JP2012221023A patent/JP5726148B2/ja active Active
-
2013
- 2013-01-30 IL IL224494A patent/IL224494B/en active IP Right Grant
-
2014
- 2014-05-26 JP JP2014108137A patent/JP6302356B2/ja active Active
- 2014-10-08 US US14/509,870 patent/US9796961B2/en active Active
-
2015
- 2015-10-02 US US14/873,296 patent/US20160040129A1/en not_active Abandoned
-
2016
- 2016-02-17 JP JP2016027812A patent/JP2016129515A/ja active Pending
-
2017
- 2017-08-31 JP JP2017166334A patent/JP6655050B2/ja not_active Expired - Fee Related
- 2017-12-24 IL IL256512A patent/IL256512B/en active IP Right Grant
-
2018
- 2018-07-23 US US16/042,904 patent/US10760055B2/en active Active
-
2019
- 2019-01-18 JP JP2019006759A patent/JP6797221B2/ja not_active Expired - Fee Related
- 2019-04-14 IL IL266009A patent/IL266009B/en active IP Right Grant
-
2020
- 2020-06-15 US US16/901,956 patent/US20200308545A1/en not_active Abandoned
- 2020-07-10 JP JP2020119082A patent/JP7078673B2/ja active Active
- 2020-11-02 IL IL278426A patent/IL278426B/en unknown
-
2022
- 2022-01-27 US US17/586,196 patent/US20220145253A1/en not_active Abandoned
- 2022-02-22 JP JP2022025236A patent/JP2022065146A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016129515A5 (ja) | ||
Yun | Changes in regenerative capacity through lifespan | |
Palechor-Ceron et al. | Conditional reprogramming for patient-derived cancer models and next-generation living biobanks | |
Bechard et al. | Subcellular localization of glycogen synthase kinase 3β controls embryonic stem cell self-renewal | |
JP2018520654A5 (ja) | ||
MY189819A (en) | Genetically modified cells and uses thereof | |
Waghray et al. | Tbx3 controls Dppa3 levels and exit from pluripotency toward mesoderm | |
JP2018518943A5 (ja) | ||
JP2018508198A5 (ja) | ||
Rasmussen et al. | Wnt signaling and its impact on mitochondrial and cell cycle dynamics in pluripotent stem cells | |
WO2015188106A3 (en) | Perfusion culturing methods and uses thereof | |
EP4306636A3 (en) | Monolayer of pbmcs or bone-marrow cells and uses thereof | |
JP2016527891A5 (ja) | ||
Kang et al. | Generation of bladder urothelium from human pluripotent stem cells under chemically defined serum-and feeder-free system | |
Lin et al. | Bovine induced pluripotent stem cells are more resistant to apoptosis than testicular cells in response to mono-(2-ethylhexyl) phthalate | |
Jeyarajah et al. | The transcription factor OVOL2 represses ID2 and drives differentiation of trophoblast stem cells and placental development in mice | |
Tang et al. | Sp5 induces the expression of Nanog to maintain mouse embryonic stem cell self-renewal | |
Yoon et al. | Generation of fibrotic liver organoids using hepatocytes, primary liver sinusoidal endothelial cells, hepatic stellate cells, and macrophages | |
JP2010166901A5 (ja) | ||
WO2016193986A3 (en) | Selective surfaces for, and methods of, selecting a population of stem and progenitor cells, and uses thereof | |
Gao et al. | Efficient Reprogramming of Mouse Embryonic Stem Cells into Trophoblast Stem-like Cells via Lats Kinase Inhibition | |
JP2015073442A5 (ja) | ||
Giallongo et al. | Engagement of Mesenchymal Stromal Cells in the Remodeling of the Bone Marrow Microenvironment in Hematological Cancers | |
Dong et al. | Glycolysis-Stimulated Esrrb Lactylation Promotes the Self-Renewal and Extraembryonic Endoderm Stem Cell Differentiation of Embryonic Stem Cells | |
Glauß et al. | A Novel Chimeric Oncolytic Virus Mediates a Multifaceted Cellular Immune Response in a Syngeneic B16 Melanoma Model |